- Home
- MYNZ vs KZIA Comparison
MYNZ vs KZIA Comparison
Compare MYNZ & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- KZIA
- Stock Information
- Founded
- MYNZ 2021
- KZIA 1994
- Country
- MYNZ Germany
- KZIA Australia
- Employees
- MYNZ N/A
- KZIA N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- MYNZ Health Care
- KZIA Health Care
- Exchange
- MYNZ Nasdaq
- KZIA Nasdaq
- Market Cap
- MYNZ 7.9M
- KZIA 9.0M
- IPO Year
- MYNZ 2021
- KZIA 1999
- Fundamental
- Price
- MYNZ $1.58
- KZIA $8.22
- Analyst Decision
- MYNZ Buy
- KZIA Strong Buy
- Analyst Count
- MYNZ 2
- KZIA 2
- Target Price
- MYNZ $14.00
- KZIA $14.00
- AVG Volume (30 Days)
- MYNZ 74.3K
- KZIA 137.3K
- Earning Date
- MYNZ 10-21-2025
- KZIA 11-14-2025
- Dividend Yield
- MYNZ N/A
- KZIA N/A
- EPS Growth
- MYNZ N/A
- KZIA N/A
- EPS
- MYNZ N/A
- KZIA N/A
- Revenue
- MYNZ $893,991.00
- KZIA $1,549,158.00
- Revenue This Year
- MYNZ $26.06
- KZIA N/A
- Revenue Next Year
- MYNZ $4.97
- KZIA $49.25
- P/E Ratio
- MYNZ N/A
- KZIA N/A
- Revenue Growth
- MYNZ N/A
- KZIA 248983.08
- 52 Week Low
- MYNZ $1.30
- KZIA $2.86
- 52 Week High
- MYNZ $16.04
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- MYNZ 42.09
- KZIA 52.60
- Support Level
- MYNZ $1.58
- KZIA $7.60
- Resistance Level
- MYNZ $1.79
- KZIA $8.88
- Average True Range (ATR)
- MYNZ 0.10
- KZIA 0.59
- MACD
- MYNZ -0.00
- KZIA 0.06
- Stochastic Oscillator
- MYNZ 6.52
- KZIA 51.08
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.